-
Product Insights
Obsessive-Compulsive Disorder - Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Obsessive-Compulsive Disorder - Global Clinical Trials Review, 2026" provides an overview of Obsessive-Compulsive Disorder Clinical trials scenario. This report provides top line data relating to the clinical trials on Obsessive-Compulsive Disorder. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Osteoporosis - Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Osteoporosis - Global Clinical Trials Review, 2026" provides an overview of Osteoporosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Osteoporosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Membranous Glomerulonephritis - Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Membranous Glomerulonephritis - Global Clinical Trials Review, 2026" provides an overview of Membranous Glomerulonephritis Clinical trials scenario. This report provides top line data relating to the clinical trials on Membranous Glomerulonephritis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Sector Analysis
Myasthenia Gravis Market Opportunity Assessment, Epidemiology, Treatment, Clinical Trials, Unmet Needs and Forecast to 2034
This report covers the 7 major markets and provides an Excel-based forecast model for the Myasthenia Gravis market through 2034. The MG market across the 7MM was valued at $4.5 billion in 2024 and is expected to grow to $13.0 billion by 2034 at a compound annual growth rate (CAGR) of 11.1%. The US represents the largest market for MG, with roughly 75.4% of sales across the seven major markets (7MM)—the US, France, Germany, Italy, Spain, the UK, and Japan—in...
-
Sector Analysis
Bio/Pharmaceutical Outsourcing Report, July 2026
Why Does Bio/Pharmaceutical Outsourcing Matter? Bio/pharmaceutical outsourcing plays an important role in pharmaceutical manufacturing, with contract manufacturing organizations (CMOs) responding to changing demand, regulatory requirements, technology investment, and supply chain dynamics. This monthly report provides analysis of the latest business conditions and developments affecting the pharmaceutical outsourcing industry. It tracks outsourcing contracts, CMO mergers and acquisitions, financing, facility openings and closures, GMP inspections, technology investments, supply chain challenges, and emerging opportunities and threats. You can use this report to: Monitor...
-
Sector Analysis
Tuberous Sclerosis Complex (TSC): Market View, Current and Future Competitive Landscape
Why Does the Tuberous Sclerosis Complex Therapeutics Market Matter? Tuberous Sclerosis Complex (TSC) is a multidisciplinary disease requiring symptom-driven management across seizures, TSC-associated tumors, and organ-specific manifestations affecting the brain, kidneys, lungs, skin, and heart. In 2025, there were 198,627 diagnosed prevalent cases of TSC-associated epilepsy across the 16 countries covered in GlobalData's epidemiology forecast. Treatment includes anti-seizure medications, dietary and surgical options for refractory epilepsy, surveillance, and supportive interventions. Marketed mTOR therapies such as everolimus and topical sirolimus are...
-
Sector Analysis
Chronic Kidney Disease in Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035
This report covers the 7MM (US, 5EU, Japan) and provides an Excel-based forecast model for the chronic kidney disease (CKD) market through 2035. GlobalData estimates the sales of CKD therapeutics to be approximately $4.3 billion across the 7MM in 2025. By 2035, GlobalData expects the CKD market to grow at a strong compound annual growth rate (CAGR) of 9.8%, reaching sales of $10.9 billion by the end of the forecast period. The major drivers of CKD market growth over the...
-
Sector Analysis
Major Depressive Disorder: Epidemiology Report and Forecast to 2035
Why Does Major Depressive Disorder Epidemiology Matter? Major depressive disorder (MDD), also known as clinical depression, is a complex mental health condition associated with persistent changes in mood, interest, cognition, and physical functioning. While treatment options include antidepressant medications, psychotherapy, and advanced neuromodulation, some patients experience treatment-resistant depression (TRD), creating distinct considerations for treatment development and market planning. Understanding the size, characteristics, and evolution of patient populations is essential for pharmaceutical companies and healthcare stakeholders evaluating the MDD treatment landscape....
-
Sector Analysis
Ireland in the IRP Crossfire
Ireland's decision to exclude the UK from its international reference pricing (IRP) basket from 2027 will exert mild downward pressure on achievable ex-manufacturer prices for innovative medicines, a GlobalData analysis of POLI data across 22 recently reimbursed products finds.
-
Thematic Analysis
Global M&A Deals in H1 2026 - Top Themes by Sector: Strategic Intelligence
Why Does M&A Activity Matter? Mergers and acquisitions can provide a view into the themes reshaping industries and where companies are directing capital and strategic investment. The global M&A market recorded $1.7 trillion in deal value in H1 2026, up 47% from H1 2025. This report analyzes the most notable transactions across major sectors and identifies the disruptive themes driving M&A activity. You can use this report to: Understand the scale and direction of global M&A activity Identify disruptive themes...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.